Physician profile
Yan Liu
NPI 1134446172
$8,596.80
in general payments reported to CMS, 2019-2025
22 companies · $321 in 2025
The $321 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2021: $108 · 2022: $6,461 · 2023: $181 · 2024: $619 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.52 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,159.55 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $389.44 | 2019-2025 | |
| Heartflow, INC. | $287.79 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $276.95 | 2019-2022 | |
| Boston Scientific Corporation | $267.96 | 2022-2025 | Watchman Flx |
| Amgen INC. | $206.93 | 2019-2024 | Repatha |
| Abiomed | $148.37 | 2019 | |
| Atricure, INC. | $146.70 | 2023 | |
| Novo Nordisk INC | $136.17 | 2024-2025 | Ozempic |
| Biotronik INC. | $121.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $79.35 | 2019-2024 | Xarelto |
| Irhythm Technologies, INC. | $63.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $55.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $49.36 | 2019-2024 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $45.36 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $39.87 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $37.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.61 | 2019 | |
| Chiesi USA, INC. | $19.00 | 2023 | Cleviprex |
| Lundbeck LLC | $14.55 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $12.57 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.